fbpx

Lipogems Have Announced Reaching 100+ Peer-Reviewed Publications That Include 3-year follow ups in Orthopaedics!

Lipogems Have Announced Reaching 100+ Peer-Reviewed Publications That Include 3-year follow ups in Orthopaedics!

Lipogems, the leading adipose tissue company in orthopaedics and arthroscopic surgery, announced this week an unprecedented milestone of 100+ peer-reviewed publications with up to 3-year follow-up highlighting the clinical and scientific data supporting Lipogems Microfragmented Fat™ (95% are independent studies from well-respected institutions around the world). This achievement represents the largest body of clinical and scientific evidence supporting any single adipose tissue technology. Lipogems is leading the way in orthopaedics by providing physicians and patients a best-in-class FDA-cleared option for patients who have tried conservative options and are not ready for major invasive surgery, known as the orthopedic treatment gap. Many patients are in the orthopaedic treatment gap for 9-20 years, including the elderly, military, highly active individuals, and vulnerable populations.

 

Read more here

Leave a Reply

Your email address will not be published. Required fields are marked *

Get in touch

Find your clinic

We offer appointments nationwide and now working with partners abroad providing cutting edge Regenerative Medicine to patients in Dubai, Australia, Spain and Pakistan.

Sign-up to receive our recent news and the latest developments in regenerative medicine.

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at info@theregenerativeclinic.co.uk. We will treat your information with respect. For more information about our privacy practices please visit our website. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.